查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1512651

全球自动化血液分析仪市场 - 2024-2031

Global automated hematology analyzer Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

2023年，全球自动化血液分析仪市场规模达到4.56亿美元，预计2031年将达到7.95亿美元，2024-2031年预测期间复合年增长率为7.2%。

自动血液分析仪是一种高度专业化的电脑化机器，可计算血液样本中不同类型的红血球和白血球、血小板、血红素和血球容积比水平的数量。

它们包括可编程自动警报系统，用于指示超出参考范围的结果。血液分析仪涉及疾病的检测、监测、预后和后续筛检，广泛应用于血友病、血癌、血栓等各种血液相关疾病。其他疾病包括白血病、贫血、输血、恶性淋巴瘤以及其他需要血液学诊断的疾病。

该市场受到血液疾病盛行率上升、技术进步以及自动化血液学仪器采用率上升等因素的推动。

市场动态：

司机

血液疾病盛行率上升

全球自动化血液分析仪市场的需求是由多种因素所驱动的。主要因素之一是血液疾病发生率的增加推动了市场的成长。澳洲政府卫生和老年护理部2022年12月报告称，每年约有33万名受影响的婴儿出生，其中83%患有镰状细胞疾病，17%患有地中海贫血，7%的准妈妈患有血红蛋白疾病，全球超过 1% 的夫妇面临风险。

根据世界血友病联合会 2023 年 10 月发布的一项研究，全球有 830,895 名男性患有血友病，其中约 2,82,266 人患有最严重的疾病，且诊断不足。当患者出现血球问题时，早期诊断和治疗是维持患者生活品质最有效的方法。

此外，产业主要参与者更加关注血液分析仪的技术优势将推动这一市场的成长。例如，2022年7月，Sysmex公司宣布推出新的样本运输系统模组，可连接到其在血液学领域的旗舰型号XR系列自动血液分析仪（XR系列）。

此外，2022年3月，迈瑞推出了全新BC-700系列，这是一款革命性的血液分析仪系列，融合了全血球计数（CBC）和红血球沉降速率（ESR）测试。该系列包括两款开放式样品瓶型号 BC-700/BC-720 和两款自动装载机型号 BC-760/BC-780，旨在为中等容量实验室提供应用于优质产品的先进诊断技术。

限制

分析仪成本高、耗时且严格的监管要求、熟练技术人员的可用性有限以及有限的报销政策等因素预计将阻碍市场的发展。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 血液疾病盛行率上升
      • 技术不断进步，自动化血液学仪器的采用率不断提高
    • 限制
      • 分析仪成本高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：依产品和服务分类

  • 仪器
  • 三部分血液分析仪
  • 5 部分血液分析仪
  • 即时检测血液分析仪
  • 其他的
  • 试剂及耗材
  • 服务

第 7 章：按类型

  • 全自动血液分析仪
  • 半自动血液分析仪

第 8 章：按申请

  • 出血性疾病
  • 血癌
  • 贫血
  • 感染
  • 免疫系统疾病
  • 其他的

第 9 章：按最终用户

  • 医院
  • 临床实验室
  • 学术及研究机构
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Beckman Coulter, Inc
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Accurex
  • Everlife CPC Diagnostics
  • Sysmex
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd
  • Abbott
  • Horiba Medical
  • Biobase Biodusty(Shandong), Co., Ltd
  • Siemens Healthineers
  • F. Hoffmann-La Roche Ltd

第 13 章：附录

简介目录
Product Code: MD8510

Overview

The global automated hematology analyzer market reached US$ 456 million in 2023 and is expected to reach US$ 795 million by 2031, growing with a CAGR of 7.2% during the forecast period 2024-2031.

Automated hematology analyzers are computerized, highly specialized machines that count the number of different types of red and white blood cells, blood platelets, hemoglobin, and hematocrit levels in a blood sample.

They include programmable automated alarm systems for indicating results outside the reference range. Hematology analyzers are concerned with the detection, and monitoring of diseases, prognosis, and subsequent screening and are extensively used against various blood-related diseases such as hemophilia, blood cancer, and blood clots. Other diseases include leukemia, anemia, blood transfusion, malignant lymphomas, and others where hematology diagnosis is used.

The market is driven by factors such as the rise in the prevalence of blood disorders, increasing technological advancements, and rising adoption rates of automated hematology instruments.

Market Dynamics: Drivers

Rise in Prevalence of Blood Disorders

The demand for the global automated hematology analyzer market is driven by multiple factors. One of the primary factors is the increase in the incidence of blood disorders driving the market growth. The Department of Health and Aged Care of the Australian Government reported in December 2022 that there were about 330,000 affected babies born every year, 83% of whom had disorders of sickle cell, 17% had thalassemia, 7% of expectant mothers had hemoglobin disorders, and more than 1% of the couples worldwide were at risk.

According to a World Federation of Hemophilia research study published in October 2023, there were a higher number of 830,895 males worldwide having hemophilia, and about 2,82,266 of these have a severe type of condition that is the most underdiagnosed. Early diagnosis, as well as treatment, are some of the most effective ways to maintain a patient's quality of life when they have a blood cell problem.

Moreover, key players in the industry more focus on the technological advantages of the hematology analyzer would drive this market growth. For instance, in July 2022, Sysmex Corporation announced the launch of new sample transportation system modules that can be connected to the XR-Series Automated Hematology Analyzer (XR-Series), its flagship model in the hematology field.

Also, in March 2022, Mindray launched the new BC-700 Series, a revolutionary hematology analyzer series that incorporates both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests. This series, including two open vial models BC-700/BC-720 and two autoloader models BC-760/BC-780, is designed to empower medium-volume laboratories with advanced diagnostics technologies that are applied in the premium products.

Restraints

Factors such as the high cost of the analyzer, time-consuming & stringent regulatory requirements, limited availability of skilled technicians, and limited reimbursement policies are expected to hamper the market.

Segment Analysis

The global automated hematology analyzer market is segmented based on product & service, type, application, and end-user.

The 3-part hematology analyzer segment accounted for approximately 65.4% of the global automated hematology analyzer market share

The 3-part hematology analyzer segment is expected to hold the largest market share over the forecast period. The 3-part hematology analyzer measures the volume of white blood cells electrically & categorizes blood cells, based on their size, divides into three groups: a small white blood cell group (lymphocytes), a medium-sized white blood cell group (monocytes, eosinophils, and basophils), & large white blood cell group. This test can be used to detect a variety of conditions, such as anemia, infection, and leukemia.

Moreover, key players in the market product launches and introducing innovative technological advancements in the hematology analyzers would drive this segment's growth. For instance, in March 2024, Agappe will launch the most advanced hematology analyzers. AG Innovate will be a customer engagement program where the customers can experience the unveiling of a revolutionary automated 3rd generation hematology analyzer and AE-powered CLIA analyzer.

Similarly, at Medlab Middle East in February 2024, Dymind is also showcasing the DH20 3-part auto hematology analyzer. Compact and user-friendly, the DH20 can measure more clinical parameters using only 9ul sample volume and comes with an optional RF card and barcode function.

Also, in April 2022, Sysmex Europe has recently launched its new three-part differential system 'XQ-320 XQ-Series Automated Hematology Analyzer', answering the needs of this important high-volume market segment. XQ-320 brings excellence in quality to a diverse range of clinical laboratory environments with reliable technology and a new level of usability.

Geographical Analysis

North America accounted for approximately 43.2% of the global automated hematology analyzer market share

North American region is expected to hold the largest market share over the forecast period owing to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the major players in this region helps to drive this market growth.

Blood Cancers are one of the driving factors in this region. According to the Leukemia and Lymphoma Society, in 2023, approximately every 3 minutes, one person in the U.S. is diagnosed with leukemia, lymphoma, or myeloma. An estimated combined total of 184,720 people in the U.S. are expected to be diagnosed with leukemia, lymphoma, or myeloma.

Moreover, key players in the industry introducing new product launches and approvals help to drive this market growth. For instance, in August 2023, Abbott received U.S. Food and Drug Administration clearance for its advanced Alinity h-series hematology system, paving the way for laboratories throughout the country to run complete blood counts (CBC) as a part of Abbott's Alinity family of diagnostic products.

Also, in January 2024, HORIBA Medical launched the new HELO 2.0 high throughput automated hematology platform which is CE-IVDR approved, with pending US FDA approval. Following the success of HORIBA Medical's previous HELO, this new generation high-end hematology range has been designed in consultation with customers to further improve and cover all needs of high throughput fully automated hematology.

Market Segmentation

By Product & Service

  • Instruments
    • 3 Part Hematology Analyzer
    • 5 Part Hematology Analyzer
    • Point-of-care Testing Hematology Analyzers
    • Others
  • Reagents & Consumables
  • Services

By Type

  • Fully-Automated Hematology Analyzers
  • Semi-automated Hematology Analyzers

By Application

  • Hemorrhagic Conditions
  • Blood Cancer
  • Anaemia
  • Infections
  • Immune Disorders
  • Others

By End-user

  • Hospitals
  • Clinical Laboratories
  • Academic and Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the automated hematology analyzer market include Beckman Coulter, Inc., Accurex, Everlife CPC Diagnostics, Sysmex, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, Abbott, Horiba Medical, Biobase Biodusty(Shandong), Co., Ltd, Siemens Healthineers and F. Hoffmann-La Roche Ltd among others.

Key Developments

  • In June 2024, Horiba expanded its line of compact hematology instruments by introducing new models that integrate Erythrocyte Sedimentation Rate (ESR) testing, enhancing diagnostic capabilities with rapid results and comprehensive disease profiling.
  • In February 2024, Dymind Biotechnology (Shenzhen, China) is introducing its breakthroughs in medical solutions for hematology, coagulation, POCT, immunology, and veterinary at Medlab Middle East 2024, including its new high-end hematology analyzer DH-800 with innovative functions.
  • In May 2023, Siemens Healthineers launched next-gen hematology analyzers, workflow barriers removed to help patients get results faster. The Atellica HEMA 570 Analyzer and the Atellica HEMA 580 Analyzer. Vital to patient care, the complete blood count (CBC) is among the most performed diagnostic tests in the lab and often provides the first indication of illness in a patient.

Why Purchase the Report?

  • To visualize the global automated hematology analyzer market segmentation based on product & service, application, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of automated hematology analyzer market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available in Excel consisting of key products of all the major players.

The global automated hematology analyzer report would provide approximately 70 tables, 69 figures, and 182 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product & Service
  • 3.2. Snippet by Type
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in Prevalence of Blood Disorders
      • 4.1.1.2. Increasing Technological Advancements and Rising Adoption Rates of Automated Hematology Instruments
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Analyzer
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product & Service

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 6.1.2. Market Attractiveness Index, By Product & Service
  • 6.2. Instruments
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. 3-Part Hematology Analyzer
  • 6.4. 5 Part Hematology Analyzer
  • 6.5. Point-of-care Testing Hematology Analyzers
  • 6.6. Others
  • 6.7. Reagents & Consumables
  • 6.8. Services

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Fully Automated Hematology Analyzers
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Semi-Automated Hematology Analyzers

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Hemorrhagic Conditions
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Blood Cancer
  • 8.4. Anaemia
  • 8.5. Infections
  • 8.6. Immune Disorders
  • 8.7. Others

9. By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Clinical Laboratories
  • 9.4. Academic and Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
  • 10.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.3.1. U.S.
      • 10.3.3.2. Canada
      • 10.3.3.3. Mexico
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Germany
      • 10.4.7.2. U.K.
      • 10.4.7.3. France
      • 10.4.7.4. Spain
      • 10.4.7.5. Italy
      • 10.4.7.6. Rest of Europe
  • 10.5. South America
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. Brazil
      • 10.5.7.2. Argentina
      • 10.5.7.3. Rest of South America
  • 10.6. Asia-Pacific
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.6.7.1. China
      • 10.6.7.2. India
      • 10.6.7.3. Japan
      • 10.6.7.4. South Korea
      • 10.6.7.5. Rest of Asia-Pacific
  • 10.7. Middle East and Africa
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
  • 10.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Service
    • 10.8.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.8.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.8.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Beckman Coulter, Inc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Accurex
  • 12.3. Everlife CPC Diagnostics
  • 12.4. Sysmex
  • 12.5. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
  • 12.6. Abbott
  • 12.7. Horiba Medical
  • 12.8. Biobase Biodusty(Shandong), Co., Ltd
  • 12.9. Siemens Healthineers
  • 12.10. F. Hoffmann-La Roche Ltd

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us